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LTBP2 null mutations in an autosomal recessive
ocular syndrome with megalocornea, spherophakia,
and secondary glaucoma
Julie De ´sir*,1,2, Yves Sznajer2,3, Fanny Depasse4, Franc ¸oise Roulez5, Marc Schrooyen4, Franc ¸oise Meire4,5,6 and
Marc Abramowicz1,2
The latent TGFb-binding proteins (LTBPs) and ﬁbrillins are a superfamily of large, multidomain proteins with structural and
TGFb-signalling roles in the extracellular matrix. Their importance is underscored by ﬁbrillin-1 mutations responsible for Marfan
syndrome, but their respective roles are still incompletely understood. We report here on two families where children from
healthy, consanguineous parents, presented with megalocornea and impaired vision associated with small, round, dislocated
lenses (microspherophakia and ectopia lentis) and myopia, as well as a high-arched palate, and, in older children, tall stature
with an abnormally large arm span over body height ratio, that is, associated features of Marfan syndrome. Glaucoma was not
present at birth, but was diagnosed in older children. Whole genome homozygosity mapping followed by candidate gene analysis
identiﬁed homozygous truncating mutations of LTBP2 gene in patients from both families. Fibroblast mRNA analysis was
consistent with nonsense-mediated mRNA decay, with no evidence of mutated exon skipping. We conclude that biallelic null
LTBP2 mutations cause the ocular phenotype in both families and could lead to Marfan-like features in older children. We
suggest that intraocular pressures should be followed-up in young children with an ocular phenotype consisting of megalocornea,
spherophakia and/or lens dislocation, and recommend LTBP2 gene analysis in these patients.
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INTRODUCTION
Marfan syndrome (MFS, MIM 154700) is a connective tissue disorder
with autosomal dominant inheritance.1 MFS typically affects the
skeletal system with a disproportionate increase in the linear growth
of long bones (tall stature with increased arm span and decreased
upper-to-lower body ratio, arachnodactyly, dolichostenomelia, pectus
deformity, and scoliosis) and joint hyperlaxity; the ocular system with
ectopia lentis in 55% of affected o18 years,2 as well as microsphe-
rophakia (small round lens) and megalocornea (large cornea) in severe
congenital forms;3,4 and the cardiovascular system with thick, elon-
gated cardiac valves and progressive aortic root enlargement. Addi-
tional features of MFS include striae distensae of the skin, a decrease in
muscle and fat mass, and a predisposition to spontaneous pneumo-
thorax. Together with progressive aortic enlargement or rupture,
these features indicate an increased elastolysis and defective tissue
repair.5 M F Si sc a u s e db ym u t a t i o n si nFBN1, whose protein product
ﬁbrillin-1 (FBN1) is a major structural component of the micro-
ﬁbrils.6 Beyond the structural defect of microﬁbrils, however, abnormal
signaling by growth factors belonging to the TGFb family have an
important role in MFS.7,8 An altered cellular behavior during develop-
ment, associated with an increased TGFb activity, is further supported
by mouse models of MFS.9 Aortic aneurysm in a mouse model of MFS
can be prevented by TGFb antagonists such as a TGFb-neutralizing
antibody or the angiotensin II type 1 receptor blocker, losartan.10
The TGFbs are synthesized as prepropolypeptides, and processed in
the Golgi apparatus into mature TGFb tightly associated with its
propeptide, the latency-associated peptide (LAP). In the extracellular
matrix, the LAP.TGFb complex is further covalently bound to a latent
TGFb-binding protein (LTBP).11 The LTBPs are a family of proteins
that show important structural homologies with the ﬁbrillins.7 They
are composed of a variety of repeated cystein-rich modules, including
an 8-cysteine modular structure found only in ﬁbrillins and LTBPs.12
Some, but not all, of the 8-cystein modules can mediate binding to
the LAP.TGFb1c o m p l e x . 13,14 Although LTBP1, LTBP3, and to a lesser
extent LTBP4 were reported to form a covalent complex with
LAP.TGFb1, LTBP2, and the ﬁbrillins do not.15 In addition, the
LTBPs and ﬁbrillins contain at least one hybrid cystein-rich domain,
which can mediate intermolecular disulﬁde bonding and may hence
have an important role in microﬁbril assembly.16 LTBP1, and pre-
sumably other LTBP molecules, is transglutaminase crosslinked to the
extracellular matrix via its amino-terminal region.7 This model allows
for ﬁne temporal and spatial regulation of TGFb sequestering or
release in the extracellular matrix. LTBP1, LTBP2, and LTBP4, interact
through their carboxy-terminal region with FBN1.7,17 LTBP2 also
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a role for LTBP2 in the regulation of elastic ﬁber assembly.18
In spite of recent advances, the biology of ﬁbrillins and related
molecules, for example, the extent of the redundancy between
molecules of the LTBP-ﬁbrillin superfamily, remains incompletely
understood. Recently LTBP2 null mutations were reported in primary
congenital glaucoma (PCG).19,20 We here report biallelic null LTBP2
mutations in patients with eye features consisting primarily of micro-
spherophakia, ectopia lentis, megalocornea, and myopia, and some
features of MFS in older children.
PATIENTS
Family 1
The proband (VI.4), a boy, was ﬁrst examined in the ophthalmology
clinic at 18 months of age because of impaired vision. Spherophakia
with infero-nasal displacement of both lenses was observed. The
cornea was abnormally large (14-mm diameter in both eyes), with
ﬂat irides and iridodonesis. There was no nystagmus, and the eye
pressure was normal (16mmHg in both eyes). There was axial myopia
(Right Eye (RE) 26.1mm, Left Eye (LE) 27.2mm at 6 years). Bilateral
phakophagia was performed at age 2 years for the lens luxation
(Figure 1d). Retinal detachment presented in both eyes 4–5 years
later and ocular hypertension developed (up to 30mmHg). A pro-
band’s sister (VI.7) was referred at age 10 months because of
megalocornea. She had good ﬁxation and no nystagmus, but mega-
locornea (14.5-mm diameter), spherophakia, iridodonesis, and axial
myopia were present. She had very deep anterior chamber, and miotic
oval pupil with no well-deﬁned border. Eye pressure was normal.
Biometry performed at the age of 5 years showed an increased axial
length of the globe (RE 27.0mm, LE 28.1mm), a deep anterior
chamber (RE 3.9mm, LE 4.4mm), and increased lens diameter
(RE 5.5mm, LE 5.6mm). Posterior lens dislocation was complete at
the age of 6 years (Figure 1b). Ocular hypertony was noticed at the age
of 8 years. The third affected child in this family (VI.8), another sister
of the proband, had good ﬁxation and no nystagmus, but presented at
the age of 18 months with axial myopia, megalocornea (14.5-mm
diameter) (Figure 1c), iridodonesis, iris anomalies (anterior synechiae
and iris mamillations), deep anterior chambers, and spherophakia
with no displacement of the lenses. Eye pressure was normal. At
5 years of age intermittent anterior dislocation of the lens in the left
eye was observed, causing acute glaucoma crises and the left lens was
extracted in emergency. Left retinal detachment developed a few weeks
after. Progressive posterior luxation of the right lens, and bilateral
ocular hypertony was observed.
Figure 1 Clinical ﬁndings. (a) Proband (VI.4) of the ﬁrst family, whose height was 184cm and arm span 204cm at the age of 14 years. (b) Ultrasound scan
of the eye of patient VI.7 showing complete posterior luxation of the lens, as well as increased sphericity and short size of the lens. (c) The eye of the
younger affected daughter (VI.8) of family 1 showing megalocornea. (d) Eye of proband (V4) showing inferonasal dislocation of the lens. (e–g)H a n d so f
patients VI.7 and VI.8 from the ﬁrst family and of proband from second family.
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European Journal of Human GeneticsThe family was referred to our Genetics department when the
proband was 14 years of age. The parents were ﬁrst cousins of
Moroccan descent. The proband’s height was 184cm, with an
increased arm span of 204cm, and a decreased upper to lower body
ratio (83cm/101cm) (Figure 1a). The hands were normal, with
relatively long ﬁngers (Figure 1e and f), albeit no frank arachno-
dactyly as the Walker sign (wrist sign) and Steinberg sign (thumb sign)
were not present. The face was elongated. The palate was high-arched.
The upper-to-lower body ratio was normal in both sisters with similar
ocular abnormalities. The skin was normal on physical examination,
with no striae distensae. The teeth and gums were unremarkable. The
parents presented no features of MFS or Weill–Marchesani syndrome.
Ophthalmological evaluation was normal in both parents and in the
other six siblings. It is interesting to note that the proband and
the older affected sister was in a special education school, and their
IQ were just at or below normal (75 and 68, respectively). The
younger affected sister had no systematic evaluation of mental
capacities because psychomotor development and education were
normal. Intelligence was normal in all other members of the family.
A heart ultrasound showed a normal heart with normal valves and
a normal aortic root in the proband and both affected sisters.
Respiratory function tests were normal in the proband. No increased
level of homocystine was found in the urine. A skin biopsy was
performed for ﬁbroblast culture. Marfan syndrome was considered
and direct analysis of the FBN1 gene was performed, but no mutation
was identiﬁed. The clinical parameters are shown in Table 1.
Family 2
We examined a second family of Macedonian descent with two
children, one boy in good health and one affected girl. She was
referred at age 26 months because of megalocornea. On ophthalmic
examination the diameter of her corneas was 14mm bilaterally.
Slit lamp examination revealed a few patches of iris atrophy with
iris transillumination and a very ﬂat anterior chamber. The latter
was associated with an anterior and superior dislocation of the lens.
The lenses were abnormally round (spherophakia). The fundus
and the eye pressure were normal. Biometry showed normal axial
length of 21.91mm (RE) and 22.5mm (LE) (normal values for
this age 21.63mm±0.77). Keratometry was within normal range
(mean of 42.5 D RE and 43.37 D LE). Her refraction was hyperme-
tropic with astigmatism in the right +16 (+7 1351) and in the left eye
+12 (+7 451). An iridectomy was performed but the anterior chamber
remained very shallow. A clear lens was extracted to prevent acute
angle closure glaucoma and to improve vision. At the age of 3 years, so
far she did not develop glaucoma. At 2½ years, her arm span was
87cm, with a height of 88cm and a sitting height of 51cm, giving
normal arm span/height ratio and sitting height/height ratio for age.
The hands were unremarkable (Figure 1g). The face was normal. The
palate was high-arched. The skin was normal, with no striae distensae.
The teeth and gums were unremarkable. Psychomotor development
was normal (sitting at 5 months, walking at 1 year, speaking two
languages). A heart ultrasound showed a normal heart with normal
valves and a normal aortic root. The clinical parameters are shown in
Table 1.
METHODS
A peripheral blood sample was obtained for genetic analysis with informed
consent from the parents, and from the patients and unaffected siblings when
old enough to consent, according to our study protocol as approved by the
ethical committee of ULB – Ho ˆpital Erasme. Control DNA subjects from
Moroccan and Caucasian origin were recruited from our Genetic Centre and
from a cohort of volunteers recruited in the Department of Occupational
Medicine of our institution. Leukocyte DNA was extracted by the standard
phenol–chloroform method.21 DNA samples were puriﬁed using the QiaAmp
DNA microkit and resuspended in Tris-HCl buffer. A genome-wide search for
homozygosity was performed in the affected siblings of family 1 using an
Affymetrix 10K GeneChip microarrays of 10000 autosomal single nucleotide
polymorphisms (Affymetrix UK Ltd, High Wycombe, UK) following the
instructions of the manufacturer. Regions of homozygosity were delineated
using the Excludear algorithm.22 In chromosomal regions with apparent
homozygosity by descent, additional microsatellites were genotyped in indivi-
dual subjects. Marker order was obtained from the Cooperative Human
Linkage Center genetic map (http://gai.nci.nih.gov/CHLC/) and from the
University of California at Santa Cruz (UCSC) physical map (http://genome.
ucsc.edu/cgi-bin/hgGateway). DNA was ampliﬁed by PCR using 15ng of DNA
from each individual in a ﬁnal volume of 15ml, followed by polyacryl-
amide gel electrophoresis and silver staining. A multipoint LOD score was
computed using the MAPMAKER/HOMOZ software postulating a gene
frequency of 0.005 and marker allele frequencies as observed in a series of
control subjects, with a minimal minor allele frequency of 0.10. The 36 coding
exons and intron/exon junctions of LTBP2 were ampliﬁed using primers
designed by the ExonPrimer Perl script engine (Munchen, Germany).
Polymerase chain reaction products were puriﬁed using the Exosap-IT kit
(USB, Cleveland, OH, USA) and directly sequenced by the Big Dye Terminator
Table 1 Clinical parameters
Clinical features Family I; VI.4 Family I; VI.7 Family I; VI.8 Family II
Megalocornea (No13mm) 14/14 15/15 14.5/14.5 14/14
Lens dislocation Nasal/nasal Inferonasal/inferonasal Inferonasal/inferonasal Anterosuperior/anterosuperior
Microspherophakia +/+ +/+ +/+ +/+
Axial length of eye (mm) 26.1/27.2 27.0/28.1 22.0/24.0 21.91/22.5
Retinal detachment +/+ / /+ /
Glaucoma (age at onset) 6 years 8 years 5 years No glaucoma at 3 years
Visual acuity 5/10/1/20 4/10/4/10 1/20/2/10 Not evaluateda
Height (cm) (age) 184 (14 years) 138 (9 years) 117.5 (5 years) 88 (2 years 4/12)
U/L or SH/Hb 2SD +0.5SD 1SD 1SD
High-arched palate + + + +
Aortic root ectasia   
Cardiac valvular anomalies   
Cognitive defect (IQ) At limit (75) Mild (68) Not evaluated, normal development Not evaluated, normal development
aThe child was not compliant to test visual acuity, but she looked objects at 10cms of her eyes before lens was extracted.
bU/L: Upper/Lower body ratio; SH/H: Sitting Height/Height.
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European Journal of Human Geneticscycle sequencing kit v2 (Applied Biosystems, Foster City, CA, USA). Sequen-
cing products were puriﬁed on Egde Biosystems Performa DTR Ultra 96-Well
Plate Kit columns (Sopachem, Eke, Belgium) and analyzed on a 3130 Genetic
Analyzer sequencing machine (Applied Biosystems). Sequences were inspected
in silico for mutations using the SeqScape software version 2.0 (Applied
Biosystems).
Skin ﬁbroblasts of the proband were primary cultured using standard
procedures. The cells were then lyzed in TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) and the cellular RNA was extracted by a conventional phenol–
chloroform method. The RNAwas reverse-transcribed in single-stranded cDNA
using the SuperScript First Strand Synthesis System kit for RT-PCR (Invitrogen).
The second cDNA strand was synthesized and a PCR was performed using Taq
DNA polymerase (Invitrogen), to amplify a 625-bp fragment of LTBP2 cDNA
with direct primer situated in exon 7 and reverse primer in exon 12 (Direct
primer sequence: ACAGCAACAACATCCCTGC; Reverse primer sequence:
GCGTAGGTGTAGCCGTGG). The ampliﬁed products were detected by run-
ning a 1% agarose gel with Lambda DNA/Hind III and PhiX 174 DNA/HaeIII
Mix molecular weight marker (NEB). The gels were stained in ethidium
bromide, observed under UV transilluminator and then photographed.
RESULTS
Family 1
The initial homozygosity mapping performed in the three patients
of the ﬁrst family using the 10K GeneChip identiﬁed two large
homozygous segments, on 9q31.3–q33.2 and on 14q23.3–24.3. We
re-analyzed these regions with microsatellite markers in all family
members. This showed that the 9q31.3–q33.2 region was also homo-
zygous in an asymptomatic brother, with normal habitus and in
whom ophthalmologic examination was normal. Assuming complete
penetrance of the trait, we hence rejected linkage to chromosome 9
and considered the 14q region only (Figure 2). A maximal multipoint
LOD score of 2.87 at D14S1002 was calculated using the MAP-
MAKER/HOMOZ software. The 14q linkage segment contained 199
annotated genes. Computer-assisted in silico inspection using the
Endeavour software program,23 indicated LTBP2 gene as a strong
candidate. Direct sequencing of LTBP2 identiﬁed a homozygous
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Figure 2 Linkage analysis in family 1. The parents were second cousins. The 14q linkage region was initially identiﬁed by a genome-wide 10K GeneChip
microarray of SNPs in three affected siblings, then further analyzed by microsatellite polymorphisms in affected and unaffected siblings and parents, as
shown. A single linkage region was found where all patients and no unaffected siblings were homozygous, yielding a maximal multipoint LOD score of
2.87 at D14S1002.
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premature stop codon (c.1796dupC; p.Val600GlyfsX2). Both parents
were heterozygous for the mutation, and no unaffected sibling was
homozygous. The mutation was not found in 100 Moroccan control
subjects (Figure 3). A fragment of the LTBP2 mRNA encompassing
exons 7 through 12, that is, surrounding the frameshift mutation and
premature stop codon in exon 9, was ampliﬁed from the proband’s
cultured skin ﬁbroblasts by RT-PCR. A band of the expected size
(625bp) was observed in unrelated controls. This band was absent in
the patient, and no other band was detected (Figure 3). This result is
consistent with nonsense-mediated mRNA decay.
Family 2
In the second family, direct sequencing of the LTBP2 gene identiﬁed a
homozygous nonsense mutation in exon 4 (c.895C4T; p.Arg299X).
Both parents were heterozygous carriers of the mutation, which was
absent from 100 Caucasian controls (Figure 3).
DISCUSSION
We found biallelic LTBP2 null mutations in two unrelated families
ascertained via the ophthalmology clinic. Megalocornea and micro-
spherophakia with early ectopia lentis probably secondary to the small
round lens appears to be the most speciﬁc ﬁndings in these families.
Megalocornea and microspherophakia may be encountered in con-
genital Marfan syndrome,3,4 but the incidence in the total Marfan
population is probably very low. Megalocornea was present in all
LTBP2-mutated patients reported to date.19,20 However, the patients
in this report presented no corneal clouding, contrary to the patients
previously reported.19,20 Megalocornea with microspherophakia is a
condition that must be considered in the differential diagnosis of
PCG.24 Glaucoma may be congenital or may develop during child-
hood. The pathogenesis of the glaucoma is incompletely understood
and normal gonioscopy can be found with megalocornea.25 Recurrent
attacks of pupillary block may lead to the development of glaucoma at
a very young age and may therefore be clinically misdiagnosed as
PCG. Glaucoma in our patients developed later than previously
reported:19,20 after the age of 5 years in Family 1, not present at
3 years in Family 2. The intraocular pressures were normal in all
patients at initial evaluation. Glaucoma was thus secondary, not
primary nor congenital. Microspherophakia was identiﬁed by biome-
try and by biomicroscopy (after pupil dilatation the edge (equator) of
each crystalline lens was easily visible with slit lamp). Spherophakia
and iridodonesis were already present at the age of 10 months,
and dislocation developed in all 8 eyes beginning as early as the age
of 2 years, with inferonasal and backward displacement, producing
an image of broken zonule, as in homocystinuria in Family 1. The
displacement was anterosuperior in Family 2. Complete posterior
lens dislocation occurred in 3 of 8 eyes.
Some signs of increased growth of the long bones were seen in older
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Figure 3 LTBP2 gene sequencing and mRNA analysis. (a) Family 1. Top to bottom, direct sequencing of genomic DNA from father, proband, and an
ethnically matched unrelated control, showing c.1796_1797insC (p.Val600GlyfsX2) mutation in exon 9 of LTBP2, heterozygous in father and homozygous in
proband. (b) Family 2. Top to bottom, direct sequencing of genomic DNA from father, proband, and an ethnically matched unrelated control, showing
c.895C4T (p.Arg299X) mutation in exon 4 of LTBP2, heterozygous in father and homozygous in proband. (c) Analysis of LTBP2 transcript in cultured
ﬁbroblasts using primers situated in exons 7 and 12. 1–3: RT-PCR of three aliquots of mRNA extracted from ﬁbroblasts culture of Family 1’s proband; 4–5:
RT-PCR of two unrelated control ﬁbroblast cultures, showing a band of expected size (625bp); 6: Negative control with H2O used in place of mRNA
template; 7: Lambda DNA/Hind III and PhiX 174 DNA/HaeIII Mix molecular weight marker.
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heights of his mother and father (165 and 172cm), a slender habitus,
and an arm span of 204cm, giving an arm span/height ratio of 1.11
(Normalo1.05). An arm span greater than height was present in his
8-year-old sister, perhaps indicating a progression of increased linear
growth over time. Thus, some MFS features could be part of the
LTBP2 defect-associated phenotypic spectrum. Although ectopia lentis
and marfanoid habitus were found in some of the recently reported
patients, including tall stature, an arm span greater than height, and
arachnodactyly, no detailed data were provided.19,20 Interestingly,
none of the patients had cardiovascular symptoms, and all had a
normal cardiac ultrasound. The skin did not show striae distensae.
Therefore, we found no evidence of intense elastolysis and defective
tissue repair as reported in MFS.9 This is in line with in vitro data
showing that LTBP2 is not able to form a covalent complex with
LAP.TGFb1.15
LTBP2 is expressed in the trabecular meshwork and ciliary pro-
cesses, with a high expression in the lens capsule/lens epithelium layer
in the adult mouse, cow’s eye19 and in the human eye.20
Isolated, non-syndromic familial ectopia lentis has been reported as
an autosomal recessive trait associated with ADAMTSL4 mutations,26
or as an autosomal-dominant trait-associated with FBN1 mutations.27
Ectopia lentis is reported in MFS, and in Weill–Marchesani syndrome
(MIM277600), a rare connective tissue disorder characterized by
short stature, brachydactyly, joint stiffness, and lens abnormalities,
associated with ADAMTSL10 gene mutations.28 It is also a feature of
homocystinuria (MIM236200) and of sulfocysteinuria (MIM272300).
The two latter disorders suggest that ectopia lentis may result from a
chemical alteration of disulﬁde bonds in the microﬁbrillar network of
the ocular zonule that are essential for holding the lens in a dynamic
equilibrium. Taken together, we speculate that LTBP2 and FBN1 might
have partially redundant structural functions in the zonule, with
additional modelling by ADAMTS10 and possibly other proteases.
The zonule and the periodontal ligament share the feature of being
rich in microﬁbrils and devoid of elastin.29 Therefore, we thoroughly
examined the teeth, periodontal sulci and gingivae in our patients, but
found no abnormality.
The older two affected sibs in family 1 had an IQ just at or below
the normal range. It is presently unclear whether mental or develop-
mental delay co-segregates with the LTBP2 defect, as the third affected
child in family 1 as well as the patient in family 2 had normal
milestones.
Mutation c.1796dupC (p.Val600GlyfsX2) found in Moroccan
Family 1 affects the hybrid domain and has not been reported before.
No Moroccan patients with LTBP2 mutations have been reported to
date.19,20 Mutation c.895C4T (p.Arg299X) found in family 2 was
recently described in PCG patients from Pakistan and in European
Gypsies.19 The parents in Family 2 are Macedonian Gypsies, not
known to be related. The region where they originated from (Skopje
and Chtip) encompasses gypsy minorities (http://en.wikipedia.org/
wiki/Roma_in_the _Republic_of_Macedonia). This ﬁnding suggests
that the p.R299X LTBP2 defect may represent an ancient founder
mutation and may present either as PCG or as megalocornea,
spherophakia, and secondary glaucoma.
Both mutations are predicted to produce truncated proteins. To
date, 5 of the 6 LTBP2 mutations reported, and the mutation
p.Val600GlyfsX2 affecting the hybrid domain, are located in the
amino-terminal part of the protein, interfering with both ﬁbrillin-1
and ﬁbulin-5 binding.19,20 So far, only one mutation has been
described affecting only its carboxy-terminal domain, suggesting
that interference with ﬁbulin-5 alone can be deleterious.20 The
relatively mild phenotype of these null mutations in man contrasts
with in utero lethality of ltbp2/ mice, that die between embryonic
day 3.5 (E3.5) and E6.5.29 LTBP2 is a very large, highly repetitive
molecule, and many of its modules are encoded by single, in-frame
exons.11 No evidence of exon skipping was found in family 1
(Figure 3).
In summary, here we report homozygous null mutations of LTBP2
in two unrelated families from different ethnic backgrounds, asso-
ciated with an autosomal recessive syndrome of microspherophakia
and progressive ectopia lentis, myopia and no primary congenital
glaucoma, as well as some Marfan features in the older patient.
Glaucoma developed after the age of 5 years in the ﬁrst family. We
suggest that intraocular pressure should be followed-up in young
children with megalocornea, spherophakia and/or lens dislocation.
LTBP2 gene analysis should be offered to these patients.
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